397 related articles for article (PubMed ID: 22163278)
1. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI.
O'Bryant SE; Xiao G; Barber R; Huebinger R; Wilhelmsen K; Edwards M; Graff-Radford N; Doody R; Diaz-Arrastia R; ;
PLoS One; 2011; 6(12):e28092. PubMed ID: 22163278
[TBL] [Abstract][Full Text] [Related]
2. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
3. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset.
Johnstone D; Milward EA; Berretta R; Moscato P;
PLoS One; 2012; 7(4):e34341. PubMed ID: 22485168
[TBL] [Abstract][Full Text] [Related]
4. A blood-based algorithm for the detection of Alzheimer's disease.
O'Bryant SE; Xiao G; Barber R; Reisch J; Hall J; Cullum CM; Doody R; Fairchild T; Adams P; Wilhelmsen K; Diaz-Arrastia R;
Dement Geriatr Cogn Disord; 2011; 32(1):55-62. PubMed ID: 21865746
[TBL] [Abstract][Full Text] [Related]
5. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
6. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.
Trojanowski JQ; Vandeerstichele H; Korecka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter WZ; Weiner MW; Jack CR; Jagust W; Toga AW; Lee VM; Shaw LM;
Alzheimers Dement; 2010 May; 6(3):230-8. PubMed ID: 20451871
[TBL] [Abstract][Full Text] [Related]
7. Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention.
Udeh-Momoh C; Zheng B; Sandebring-Matton A; Novak G; Kivipelto M; Jönsson L; Middleton L
J Prev Alzheimers Dis; 2022; 9(1):12-21. PubMed ID: 35098969
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
9. Combining select neuropsychological assessment with blood-based biomarkers to detect mild Alzheimer's disease: a molecular neuropsychology approach.
Edwards M; Balldin VH; Hall J; O'Bryant S
J Alzheimers Dis; 2014; 42(2):635-40. PubMed ID: 24916542
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein E4 serum concentration for increased sensitivity and specificity of diagnosis of drug treated Alzheimer's disease patients vs. drug treated parkinson's disease patients vs. age-matched normal controls.
Goldknopf IL; Park HR; Sabbagh M
Curr Alzheimer Res; 2012 Dec; 9(10):1149-67. PubMed ID: 22950864
[TBL] [Abstract][Full Text] [Related]
11. Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.
Saddiki H; Fayosse A; Cognat E; Sabia S; Engelborghs S; Wallon D; Alexopoulos P; Blennow K; Zetterberg H; Parnetti L; Zerr I; Hermann P; Gabelle A; Boada M; Orellana A; de Rojas I; Lilamand M; Bjerke M; Van Broeckhoven C; Farotti L; Salvadori N; Diehl-Schmid J; Grimmer T; Hourregue C; Dugravot A; Nicolas G; Laplanche JL; Lehmann S; Bouaziz-Amar E; ; Hugon J; Tzourio C; Singh-Manoux A; Paquet C; Dumurgier J
PLoS Med; 2020 Aug; 17(8):e1003289. PubMed ID: 32817639
[TBL] [Abstract][Full Text] [Related]
12. Serum Protein-Based Profiles as Novel Biomarkers for the Diagnosis of Alzheimer's Disease.
Yu S; Liu YP; Liu HL; Li J; Xiang Y; Liu YH; Jiao SS; Liu L; Wang Y; Fu W
Mol Neurobiol; 2018 May; 55(5):3999-4008. PubMed ID: 28567666
[TBL] [Abstract][Full Text] [Related]
13. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
[TBL] [Abstract][Full Text] [Related]
14. Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer's Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer's Disease Clinical Studies.
Sato K; Mano T; Ihara R; Suzuki K; Niimi Y; Toda T; Iwatsubo T; Iwata A
J Prev Alzheimers Dis; 2021; 8(4):503-512. PubMed ID: 34585226
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.
Shaw LM; Vanderstichele H; Knapik-Czajka M; Figurski M; Coart E; Blennow K; Soares H; Simon AJ; Lewczuk P; Dean RA; Siemers E; Potter W; Lee VM; Trojanowski JQ;
Acta Neuropathol; 2011 May; 121(5):597-609. PubMed ID: 21311900
[TBL] [Abstract][Full Text] [Related]
17. Progression along data-driven disease timelines is predictive of Alzheimer's disease in a population-based cohort.
Venkatraghavan V; Vinke EJ; Bron EE; Niessen WJ; Ikram MA; Klein S; Vernooij MW;
Neuroimage; 2021 Sep; 238():118233. PubMed ID: 34091030
[TBL] [Abstract][Full Text] [Related]
18. Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.
Kim HJ; Park KW; Kim TE; Im JY; Shin HS; Kim S; Lee DH; Ye BS; Kim JH; Kim EJ; Park KH; Han HJ; Jeong JH; Choi SH; Park SA
J Alzheimers Dis; 2015; 48(4):1043-50. PubMed ID: 26444752
[TBL] [Abstract][Full Text] [Related]
19. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
20. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]